Overall rank by patents
#24,309
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 7 technology areas, active 2022–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
The verdict
F-star holds 11 US patents across 7 technology areas, rank #24,309 of 50,000 tracked assignees.
F-star Therapeutics Limited has been granted 11 US utility patents between 2022 and 2025, placing F-star Therapeutics Limited at rank #24,309 across all assignees tracked by PlainPatent. This portfolio spans 7 distinct Cooperative Patent Classification (CPC) subclasses, averaging 21.6 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, F-star Therapeutics Limited is one of the more focused assignees in the PatentsView dataset. By volume, F-star sits between Evolv Technologies, Inc. (11 patents, rank #24,305) and Finis Inc. (11 patents, rank #24,313) - the closest US assignees by grant volume. The composite Innovation Score of 50.9/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2022 through 2025, with 11 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. F-star Therapeutics Limited's 21.6 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 7 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark F-star Therapeutics Limited against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Evolv Technologies, Inc.
11 patents
Exinda Networks PTY, Ltd.
11 patents
ExlService Holdings, Inc.
11 patents
Ezaki Glico Co. Ltd.
11 patents
FAMILY INADA CO., LTD.
11 patents
FIBERHOME TELECOMMUNICATION TECHNOLOGIES CO., LTD
11 patents
FIBERTEX PERSONAL CARE A/S
11 patents
FINIS INC.
11 patents
F-star Therapeutics Limited
11 patents
What this shows F-star holds 11 patents at rank #24,309, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
F-star's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
51 Top 12% higher than 88% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 3 | 27.3% |
| 2023 | 7 | 63.6% |
| 2025 | 1 | 9.1% |
Top 7 of 7 technology areas
Overall rank by patents
#24,309
Across all tracked assignees
50.9 out of 100
How to use this portfolio
F-star's 11 grants land it in the top 12% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.